Esbriet

A post-hoc analysis of data from Phase 3 studies shows that Esbriet (pirfenidone) can significantly reduce the incidence of disease progression events in people with idiopathic pulmonary fibrosis (IPF) — including ... Read more

September 12, 2017September 12, 2017

Ofev-Esbriet Combo Is as Safe as Individual Components as a Pulmonary Fibrosis Therapy, Trial Indicates

Esbriet, News

A combination of Ofev (nintedanib) and Esbriet (pirfenidone) is as safe a therapy for idiopathic pulmonary fibrosis as the individual components alone, a Phase 4 clinical trial indicates. Preliminary trial findings ... Read more

August 10, 2017August 10, 2017

FibroGen Shares Positive Results of Phase 2 Trial of Investigational Therapy Pamrevlumab

Esbriet, News

A Phase 2 trial testing the investigational therapy pamrevlumab (FG-3019) in patients with idiopathic pulmonary fibrosis (IPF) has shown positive and encouraging results, FibroGen, the drug’s developer, announced. In addition, combining ... Read more

July 20, 2017July 20, 2017

Esbriet, Ofev Safety Profiles in Routine Practice Similar to Clinical Trial Reports, Study Finds

Esbriet, News

Patients with idiopathic pulmonary fibrosis (IPF) prescribed Ofev (nintedanib) or Esbriet (pirfenidone) in real-world practice have shown similar tolerability and adverse event profiles as those reported in large-scale clinical ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain Only Effective IPF Therapies Though PRM-151 is Gaining Ground, Comparison Study Finds

Esbriet, News

Esbriet (pirfenidone) and Ofev (nintedanib) remain the most reliably effective treatments for idiopathic pulmonary fibrosis (IPF), according to a study that used a time-course model to compare the effectiveness ... Read more

June 30, 2017June 30, 2017

Measures of IPF Therapy Effectiveness Should Include Patients’ Views of Success, Researchers Argue

Esbriet, News

Clinical trials of idiopathic pulmonary fibrosis (IPF) therapies should include measures that reflect patients’ views of the success of treatments, Columbia University Medical Center researchers contend. In particular, the trials should ... Read more

June 29, 2017June 29, 2017

European Commission Approves New Esbriet Tablet for IPF Treatment

Esbriet, News

The European Commission (EC) recently approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). According to Roche, Esbriet’s developer, the ... Read more

June 12, 2017June 12, 2017

Esbriet Stops Lung Fibrosis By Improving Functioning of Mitochondria, Study Shows

Esbriet, News

Esbriet (pirfenidone) stops the lung scarring in idiopathic pulmonary fibrosis (IPF) by improving the functioning of mitochondria, cell components that convert food to energy and regulate cell death, according to ... Read more

May 24, 2017May 25, 2017

Latest IPF Studies Also Support Esbriet for More Severe Lung Function Impairment

Esbriet, News

Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF). The results ... Read more